论文部分内容阅读
目的探讨结肠癌根治性术后腹腔淋巴化疗联合静脉化疗的疗效。方法对210例结肠癌患者行根治性手术后按年限分为3组,即A组犤腹腔注入氟尿嘧啶(5-FU)、丝裂霉素(MMC)和顺铂(DDP)犦、B组(腹腔注入上述化疗药物加干扰素α-2b)和C组(腹腔注入上述化疗药物加静脉注入垂体后叶素和氟尿嘧啶),对比分析3组患者的疗效。结果C组术后腹膜后淋巴结转移40.0%,明显低于A组(72.9%)和B组(72.9)(P<0.01)。C组的术后3年生存率为82.2%,明显高于A组(68.8%)和B组(64.4%)(P<0.01)。而化疗不良反应3组间差异无统计学意义。结论腹腔淋巴化疗联合静脉化疗可提高患者3年生存率。
Objective To investigate the curative effect of postoperative radical celiac lymphatic chemotherapy combined with intravenous chemotherapy in patients with colon cancer. Methods 210 cases of colon cancer patients underwent radical surgery were divided into three groups according to the age, that is, group A 犤 intraperitoneal injection of 5-fluorouracil (5-FU), mitomycin (MMC) and cisplatin (DDP) Intraperitoneal injection of the above chemotherapy drugs plus interferon α-2b) and C group (intraperitoneal injection of the above chemotherapy drugs and intravenous injection of vasopressin and fluorouracil), comparative analysis of the efficacy of three groups of patients. Results Postoperative retroperitoneal lymph node metastasis in group C was 40.0%, which was significantly lower than that in group A (72.9%) and group B (72.9) (P <0.01). The 3-year survival rate of group C was 82.2%, which was significantly higher than that of group A (68.8%) and group B (64.4%) (P <0.01). There was no significant difference between the three groups in adverse reactions of chemotherapy. Conclusion Intraperitoneal lymphatic chemotherapy combined with intravenous chemotherapy can improve the 3-year survival rate of patients.